Browse All

Current Filters

CLEAR FILTER x

TITLE

Long-term Effect of Ofatumumab Treatment on Serum Neurofilament Light Chain Levels and NEDA-3 Status in Patients With RMS: Results From ASCLEPIOS I/II and ALITHIOS

Author:Alvarez, Enrique   Kuhle, Jens   Kappos, Ludwig   Ziemssen, Tjalf   Arnold, Douglas   Cross, Anne   Boer, Ibolya   Das Gupta, Ayan   Hu, Xixi   Kukkaro, Petra   Kieseier, Bernd   Zielman, Ronald   Hauser, Stephen   

Session Name:P6: MS Clinical Trials  

Topic:MS and Inflammatory Disease  

Program Number:P6.013  

Author Institution:Department of Neurology, Rocky Mountain MS Center at the University of Colorado, Aurora, CO  Neurology, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head, Spine and Neuromedicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland  Center of Clinical Neuroscience, Department of Neurology, University Clinic Carl Gustav Carus, Dresden, Germany  McConnell Brain Imaging Centre, Montreal Neurological Institute and Hospital, McGill University and NeuroRx Research, Montreal, QC, Canada  Washington University School of Medicine, Saint Louis, MO  Novartis Pharma AG, Basel, Switzerland  Novartis Healthcare, Hyderabad, India  Novartis Pharmaceuticals Corporation, East Hanover, NJ  Novartis Pharma B.V., Amsterdam, Netherlands  UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA  

Results of a Phase III, Multinational, Double-blind, Placebo-controlled Study in Subjects with Relapsing Forms of Multiple Sclerosis (RMS) to Assess the Efficacy, Safety, and Tolerability of GA Depot, a Long-Acting IM Injection of Glatiramer Acetate, Admi